Aeterna Zentaris Inc. (NASDAQ:AEZS) is trading in a narrow range so far Monday trying to put together two winning days in a row. Is a bounce in store?
As of 12.19, AEZS stock is trading up by 0.45% at $0.8751. More than 745K shares have been traded hands. The stock has moved within a range of $0.8500-$0.8888.
AEZS Issues News
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a Potential New Treatment Option for Patients with Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig’s Disease)
- AEZS announced the commencement of the previously announced preclinical program to qualify macimorelin for clinical development as a potential treatment option for amyotrophic lateral sclerosis (ALS; Lou Gehrig’s disease).
- The preclinical development program is part of the recently executed Material Transfer Agreement (MTA) with The University of Queensland (“The University”).
- The University researchers, led by Frederik Steyn, MSc, PhD, will conduct preclinical studies in disease-related in-vitro and in-vivo models of ALS to demonstrate the therapeutic potential of macimorelin on disease progression and ALS-specific pathology.
Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris, commented, “The start of the preclinical phase represents a significant milestone in the development of a potential new treatment option for ALS to help patients with this terrible, incurable disease and to improve their quality of life. We look forward to supporting Dr. Steyn’s research team in addressing this significant unmet medical need.”
|SHARES OUTSTANDING||121.15 M|
|SHARE FLOAT (%)||121.04 M (99.91%)|
|% HELD BY INSTITUTIONS||3.21|
Recent Stock Performance
|+/- EMA(20)||0.96 (-9.37%)|
|+/- SMA(50)||1.07 (-18.69%)|
|+/- SMA(200)||0.71 (+22.54%)|
|CCI20||-90.3294||Sell||Chaikin Money Flow||0.0639||Buy|
|MACD||-0.0515||Sell||Money Flow Index||38.9527||Sell|
|STOCH (14,3)||14.4507||OverSold||STOCH RSI||0.4813||Buy|